Shares of OncoGenex Pharmaceuticals Inc. (OGXI) were down over 32% in extended trading on Wednesday, following failure of a phase II trial of the company’s drug candidate Apatorsen in combination with chemotherapy drugs Carboplatin and Pemetrexed in patients with untreated metastatic non-small cell lung cancer.